|
ACCT
Amlodipine Cardiovascular Community Trial
 |
Author(s) |
Kloner RA, Sowers JR, DiBona GF, Gaffney M, Wein M
|
 |
Title(s) |
Sex- and age-related antihypertensive effects of amlodipine
|
|
Reference(s) |
Am J Cardiol 1996;77:713-22
|
|
Disease |
Mild to moderate hypertension
|
|
Purpose |
To assess whether there were age, sex, or race differences in response to amlodipine in patients with mild to moderate hypertension
|
|
Study design |
Open
|
|
Follow-up |
16 weeks
|
|
Patients |
1084 patients (79% white, 21% black), aged 21-80 years
|
|
Treatment regimen |
Amlodipine, 5-10 mg daily
|
|
Results |
At the end of the 4-week titration/efficacy phase, mean ± SD blood pressure had decreased by <tik-alt-045-dit-format-minteken> -</tik-alt-045-dit-format-minteken> 16.3 ± 12.3/<tik-alt-045-dit-format-minteken> -</tik-alt-045-dit-format-minteken> 12.5 ± 5.9 (p ≤ 0.0001). Amlodipine produced a goal BP response (sitting diastolic ≤ 90 mm Hg or a 10 mm Hg decrease) in 86% of the patients. The response was greater in women (91.4%) than in men (83.0%; p ≤ 0.001) and greater in patients ≥ 65 years (91.5%) than in those < 65 years (84.1%; p ≤ 0.01), but there was no significant difference between whites and blacks (86.0% vs 85.9%, respectively). The sex differences were not fully explained by differences in age, weight, dose (mg/kg), race, baseline BP, or compliance, and there were no differences between women connected with use of hormone replacement therapy. Amlodipine was well-tolerated, mild to moderate oedema being the most frequent adverse effect
|
|
|
|
